This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Hypophysitis

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Hypophysitis is a rare condition characterised by inflammation of the pituitary gland, usually resulting in hypopituitarism and pituitary enlargement (1,2,3)

  • pituitary inflammation can occur as a primary hypophysitis (most commonly lymphocytic, granulomatous or xanthomatous disease) or

  • secondary hypophysitis (as a result of systemic diseases, immunotherapy or alternative sella-based pathologies)

Caturegli et al. reviewed the disease, showed that lymphocytic hypophysitis is classified into three forms, lymphocytic adenohypophysitis (LAH), lymphocytic infundibulo-neurohypophysitis (LINH), and lymphocytic panhypophysitis (LPH) (2)

  • adenohypophysitis mainly affects the anterior pituitary
  • infundibulo-neurohypophysitis involves the posterior pituitary and stalk
  • panhypophysitis may be heterogeneous, and the pathogenesis includes local inflammation from the anterior pituitary, posterior pituitary, or pathological conditions of hypothalamic-pituitary region such as Rathke's cyst, craniopharyngioma, or germinoma

Traditionally considered a very rare condition, the recent recognition of IgG4-related disease and hypophysitis as a consequence of use of immune modulatory therapy has resulted in increased understanding of the pathophysiology of hypophysitis (1,4)

Hypophysitis usually results in acute and persistent pituitary hormone deficiency requiring long-term replacement (4)

Clinical features:

  • hypophysitis-related symptoms are:
    • headache, disturbances in visual acuity and the visual field, and hypopituitarism due to inflammation and compression of surrounding tissues by the enlarged pituitary
      • adrenocorticotropic hormone (ACTH) secretion is impaired first in most cases of hypophysitis (3)
      • increased prolactin (PRL) levels are observed, resulting in decreased luteinizing hormone/follicle stimulating hormone
      • hypogonadism also occurs by damage of gonadotrophs due to inflammation

Immunological insights:

  • anti-Rabphilin antibody has been proposed to be a biomarker for lymphocytic infundibulo-neurohypophysitis
  • immunological disorders such as anti-Pit-1 antibody syndrome are similar to the pathogenesis of lymphocytic hypophysitis - congenital combined TSH, GH, and PRL deficiency due to a Pit-1 gene mutation is a well-known cause of short stature
  • immune checkpoint blockade such ipilimumab has been shown to induce anti-CTLA-4-related hypophysitis

Management of hypophysitis includes control of the inflammatory pituitary mass using a variety of treatment strategies including surgery and medical therapy

  • glucocorticoids remain the mainstay of medical treatment but other immunosuppressive agents (e.g. azathioprine, rituximab) show benefit in some cases, but there is a need for controlled studies to inform practice (4)

Reference:

  • Lin HH et al. In situ activation of pituitary-infiltrating T lymphocytes in autoimmune hypophysitis. Sci Rep 2017; 7: 43492.
  • Caturegli P et al. Autoimmune hypophysitis. Endocr Rev 2005; 26: 599-614.
  • Hashimoto K, Takao T, Makino S: Lymphocytic adenohypophysitis and lymphocytic infundibuloneurohypophysitis. Endocr J 1997; 44: 1-10.
  • Joshi MN et al.MECHANISMS IN ENDOCRINOLOGY: Hypophysitis: diagnosis and treatment. Eur J Endocrinol. 2018 Sep;179(3):R151-R163

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.